Physician profile
Taylor Roark
NPI 1821728833
$2,644.43
in general payments reported to CMS, 2019-2025
28 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $285 · 2023: $739 · 2024: $14.89 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.36 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $422.69 | 2025 | Airsupra |
| Pfizer INC. | $257.32 | 2023-2025 | |
| Lilly USA, LLC | $241.62 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Gilead Sciences, INC. | $170.70 | 2023-2025 | Epclusa |
| Novo Nordisk INC | $135.20 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Inspire Medical Systems, INC. | $72.69 | 2025 | Inspire |
| Alkermes, INC. | $65.90 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Aimmune Therapeutics, INC. | $55.37 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $45.53 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $45.33 | 2025 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $35.77 | 2022 | |
| Orexo US, INC. | $34.08 | 2023 | Zubsolv |
| Insulet Corporation | $32.13 | 2025 | Omnipod |
| Indivior INC. | $31.40 | 2022-2023 | Sublocade |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $30.81 | 2025 | Xtampza, Belbuca |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.16 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $23.98 | 2025 | |
| Astellas Pharma US INC | $22.23 | 2025 | Veozah |
| Vertex Pharmaceuticals Incorporated | $19.80 | 2025 | |
| Amgen INC. | $19.00 | 2025 | Evenity |
| Axsome Therapeutics, INC. | $18.77 | 2025 | Symbravo |
| Actelion Pharmaceuticals US, INC. | $18.35 | 2025 | Uptravi, Opsumit |
| Daiichi Sankyo INC. | $16.37 | 2025 | Injectafer |
| Vanda Pharmaceuticals INC. | $15.85 | 2025 | Fanapt, Hetlioz |
| Tactile Systems Technology INC | $14.39 | 2025 | Nimbl, Flexitouch Plus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.62 | 2025 | Xifaxan |
| Organon LLC | $12.01 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Roark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.